GBR-13119

GBR-13119 is a psychoactive drug and research chemical of the diphenylmethane class. It acts as a potent and selective dopamine reuptake inhibitor (DRI) and is the most selective DRI known, with 1,000-fold selectivity for dopamine over norepinephrine and serotonin. GBR-13119 was developed in the 1980s by the pharmaceutical company G.D. Searle & Company.

Pharmacology

GBR-13119 is a potent inhibitor of the dopamine transporter (DAT), which is responsible for the reuptake of dopamine in the synapse. By blocking this transporter, GBR-13119 increases the amount of dopamine available in the synapse, leading to increased dopaminergic activity. This can result in effects such as increased alertness, euphoria, and increased motor activity.

Chemistry

GBR-13119 is a member of the diphenylmethane class of compounds, which also includes other DRIs such as GBR-12909 and GBR-13069. It is structurally related to these compounds, with the main difference being the substitution of a fluorine atom at the 4-position of one of the phenyl rings.

Research

Research into GBR-13119 has primarily focused on its potential use in the study of dopamine function and related disorders, such as Parkinson's disease and schizophrenia. However, its high selectivity for the dopamine transporter over other monoamine transporters has limited its clinical utility.

See also

• Dopamine reuptake inhibitor
• Diphenylmethane
• GBR-12909
• GBR-13069